News | May 26, 2016

Coherus BioSciences Advances Differentiated IP Strategy For Humira Market Access

USPTO Issued Coherus U.S. Patents 9,340,611; 9,340,612 and 9,346,880

Redwood City, CA (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced that the United States Patent and Trademark Office (USPTO) issued to Coherus U.S. Patents 9,340,611; 9,340,612 and 9,346,880. These patents generally concern formulations of adalimumab, the active biological ingredient in Coherus’ Humira biosimilar, CHS-1420, currently in Phase 3. The formulations described in these patents achieve stability without need for polyols or surfactants.

“We welcome these USPTO decisions,” said Denny Lanfear, President and Chief Executive Officer of Coherus. “The issuance of these U.S. patents, along with pending foreign counterparts, as well as the USPTO’s recent decision instituting our IPR against AbbVie’s U.S. Patent 8,889,135 validates our differentiated intellectual property strategy. We view these achievements as further confirmation of Coherus’ leadership in biosimilar intellectual property and the effectiveness of our platform. We continue to execute our plan for the development and commercialization of our Humira biosimilar, CHS-1420, consistent with our corporate strategy. These developments, along with this continued execution, reinforce our previous guidance anticipating BLA filing following successful Phase 3 completion.”

About Coherus BioSciences, Inc.

Coherus is a leading pure-play global biosimilar platform company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products, including CHS-5217 (bevacizumab biosimilar) and CHS-3351 (ranibizumab biosimilar). For additional information, please visit

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release, including statements regarding Coherus’ plans, potential opportunities, expectations, projections, goals, objectives, milestones, strategies, product pipeline, clinical studies, product development, release of data and the potential benefits of its products under development are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including Coherus’ ability to further our intellectual property strategy, and advance and commercialize CHS-1701, CHS-0214 and CHS-1420. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of our regulatory filings and other matters that could affect the availability or commercial potential of our biosimilar drug candidates, as well as possible patent litigation. Coherus undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Coherus’ business in general, see Coherus’ Annual Report on Form 10-Q for the quarter ended March 31, 2016, filed with the Securities and Exchange Commission on May 9, 2016 and its future periodic reports to be filed with the Securities and Exchange Commission.

HUMIRA® is a registered trademark of AbbVie Inc.

© 2016 GlobeNewswire, Inc. All Rights Reserved.

Source: Coherus BioSciences, Inc.